A Phase 1 Study of MLN9708 in Adult Patients With Advanced Nonhematologic Malignancies
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | March 2009 |
| End Date: | June 2012 |
An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
This is an open-label, multicenter, phase 1, dose escalation study of MLN9708. The primary
purpose of this study is to determine the safety profile, establish the maximum tolerated
dose, and inform the phase 2 dose of MLN9708 administered intravenously in patients with
nonhematologic malignancies.
We found this trial at
2
sites
Sarah Cannon Cancer Center People who live with cancer
Click here to add this to my saved trials
12902 USF Magnolia Dr
Tampa, Florida 33612
Tampa, Florida 33612
(888) 663-3488
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
Click here to add this to my saved trials